Tasly Pharmaceutical Group Taps Shuwen Biotech for Companion Diagnostic Services

Shuwen Biotech announces that Tasly Pharmaceutical Group has tapped Shuwen Biotech for clinical services and proprietary diagnostics for its oncology drug candidates.

"With the shifting economic macro-environment globally, the need for cost-saving, innovative and personalized diagnostics is more than ever before. We at Shuwen aim to add value not only to committed innovators in the pharmaceutical space like Tasly, but ultimately to all patients in need of healthcare treatments," commented Jay Z. Zhang, Chairman and CEO of Shuwen Biotech.

The two companies plan to use Shuwen’s established companion diagnostic development team and CAP-accredited reference labs to drive clinical outcomes and ultimately deliver the most innovative and life-saving solutions to patients and healthcare professionals globally.

 About Tasly
Established in 1994, Tasly is one of the largest Chinese pharmaceutical companies. Tasly offers a wide variety of pharmaceuticals and traditional Chinese medicines for treating diseases ranging from cardiovascular diseases, diabetes, to cancer. With a turnover of 4 billion US dollars and more than 10,000 employees, Tasly is listed on the Shanghai Stock Exchange.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.